Charles River Laboratories (CRL) Stock Analysis

Charles River Laboratories (CRL) is a publicly traded company in the HEALTHCARE sector. It trades at $174.67, carries a market capitalization of $8.77B. This page summarizes the public market data, fundamentals, and frequently asked questions for CRL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NYSE

Key Metrics

Market Sentiment

Charles River Laboratories currently has a Neutral sentiment score of 0.14.

About Charles River Laboratories

Charles River Laboratories International, Inc. (CRL) is a premier global provider of essential products and services tailored to the pharmaceutical, biotechnology, and medical device sectors. The company's expertise spans the entire drug development lifecycle, offering comprehensive preclinical and clinical laboratory services, as well as advanced gene and cell therapy solutions that enhance research and development efficiency. With a steadfast commitment to innovation and regulatory complian...

GNG Research Analysis

GNG Research scores Charles River Laboratories (CRL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CRL.

Frequently Asked Questions

Does CRL pay dividends?

Charles River Laboratories (CRL) does not currently pay a regular dividend.

What is CRL's market cap?

Charles River Laboratories (CRL) has a market capitalization of $8.77B with a current stock price of $174.67.